Drug: Tocilizumab (Actemra, Genentech)
Status: Approved for the treatment of chimeric antigen receptor (CAR) T-cell–induced severe or life-threatening cytokine release syndrome (CRS) in patients at least 2 years of age
Significant Information:
- Tocilizumab is a humanized interleukin-6 receptor antagonist.
- Approval was based on a retrospective analysis of pooled outcome data assessing the efficacy of tocilizumab for severe or life-threatening CAR T-cell–induced CRS in 45 patients.
- 31